LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

79.69 -1.07

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

79.21

Max

80.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+7.5% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

13B

Ankstesnė atidarymo kaina

80.76

Ankstesnė uždarymo kaina

79.69

Naujienos nuotaikos

By Acuity

34%

66%

96 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-15 17:39; UTC

Pagrindinės rinkos jėgos

Vanda Pharmaceuticals Rises on FDA Biologics License Application

2025-12-15 23:44; UTC

Rinkos pokalbiai

Gold Steady Ahead of U.S. Employment Report -- Market Talk

2025-12-15 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

2025-12-15 22:19; UTC

Rinkos pokalbiai

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

2025-12-15 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-15 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

2025-12-15 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

2025-12-15 21:28; UTC

Įsigijimai, susijungimai, perėmimai

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

2025-12-15 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

2025-12-15 21:23; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

2025-12-15 21:23; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

2025-12-15 21:23; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

2025-12-15 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

2025-12-15 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

2025-12-15 21:15; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Completes Acquisition Of Moveworks >NOW

2025-12-15 21:00; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

2025-12-15 20:57; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

2025-12-15 20:36; UTC

Rinkos pokalbiai

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

2025-12-15 20:31; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2025-12-15 20:27; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

2025-12-15 20:15; UTC

Rinkos pokalbiai

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

2025-12-15 19:22; UTC

Rinkos pokalbiai

Gold and Silver Gain to Start Week -- Market Talk

2025-12-15 18:37; UTC

Rinkos pokalbiai

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

2025-12-15 18:29; UTC

Rinkos pokalbiai

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

2025-12-15 17:58; UTC

Rinkos pokalbiai

Canada Housing Market In Search Of a Bottom -- Market Talk

2025-12-15 17:36; UTC

Rinkos pokalbiai

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

2025-12-15 17:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-15 17:36; UTC

Uždarbis

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

2025-12-15 17:30; UTC

Įsigijimai, susijungimai, perėmimai

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

7.5% į viršų

12 mėnesių prognozė

Vidutinis 86.88 USD  7.5%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

15

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

96 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat